Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
Source: View publication →
In patients with myocardial injury after non-cardiac surgery (MINS), treatment with dabigatran 110 mg twice daily significantly reduced the risk of major vascular complications without significantly increasing major bleeding.
Key Findings
Study Design
Study Limitations
Clinical Significance
MANAGE is a landmark trial as it is the first randomized controlled study to demonstrate an effective, targeted intervention for myocardial injury after non-cardiac surgery (MINS). Because MINS often presents silently without typical ischemic symptoms, its management had previously been uncertain. This trial provided crucial evidence that moderate-intensity anticoagulation can mitigate the high risk of subsequent vascular complications, establishing a foundation for actively screening high-risk surgical patients with postoperative troponin testing and initiating prophylactic therapy.
Historical Context
With millions of non-cardiac surgeries performed annually worldwide, MINS was recognized in the 2010s as a frequent and prognostically severe complication that drives 30-day mortality and long-term cardiovascular events. Prior to the MANAGE trial, the clinical approach to MINS was entirely empirical and extrapolated from guidelines for spontaneous acute coronary syndromes. MANAGE filled this critical evidence gap by testing the hypothesis that since MINS involves thrombotic mechanisms, a direct oral anticoagulant could improve cardiovascular outcomes.
Guided Discussion
High-yield insights from every perspective
How does the pathophysiology of Myocardial Injury after Non-cardiac Surgery (MINS) differ from a classic Type 1 myocardial infarction, and what is the mechanism of action of dabigatran in addressing this condition?
Key Response
MINS is predominantly characterized by supply-demand mismatch (Type 2 MI) due to surgical stress, hypotension, hypoxia, or tachycardia, rather than the acute atherosclerotic plaque rupture seen in Type 1 MI. Dabigatran is a direct thrombin (Factor IIa) inhibitor. By dampening the pro-thrombotic post-operative state, it reduces the risk of subsequent macrovascular and microvascular thrombotic events without exclusively relying on platelet inhibition.
In a post-operative patient found to have an isolated, asymptomatic troponin elevation meeting MINS criteria, how do you weigh the decision to initiate dabigatran 110 mg BID, and why was this specific dose chosen instead of standard antiplatelet therapy?
Key Response
MINS often goes unrecognized without routine screening but carries a high 30-day mortality and vascular event risk. The resident must weigh this ischemic risk against the inherent post-operative bleeding risk. The 110 mg BID dose (lower than the standard 150 mg BID used for atrial fibrillation) was specifically chosen in MANAGE to balance antithrombotic efficacy with surgical hemostasis. Dabigatran was investigated because post-operative hypercoagulability is heavily driven by thrombin generation, offering broader protection against both venous and arterial thromboembolism than antiplatelets.
The MANAGE trial utilized a broad composite primary outcome for major vascular complications. Which specific components of this composite endpoint were most heavily impacted by dabigatran, and how should this influence your long-term cardiovascular risk stratification for these patients?
Key Response
In trials with composite endpoints, efficacy is rarely driven equally by all components. Fellows must critically evaluate whether the benefit was driven by reductions in non-fatal MI, stroke, or VTE. Recognizing that MINS signals a highly vulnerable, pro-thrombotic cardiovascular state helps fellows bridge acute perioperative care to long-term secondary prevention, indicating a need for aggressive lipid lowering, blood pressure control, and potentially extended antithrombotic therapy depending on the bleeding risk profile.
Implementing the MANAGE trial findings requires routine postoperative troponin screening to identify asymptomatic MINS. Given the high potential for downstream cascade testing and unnecessary cardiology consultations, how should institutions design a screening and management pathway that maximizes benefit while minimizing low-value care?
Key Response
Most MINS is clinically silent. To treat it, one must actively screen for it (e.g., daily post-op troponins for 48-72 hours). Attendings must grapple with the systems-based practice implications of protocolizing troponin checks. A thoughtful pathway requires clear criteria for when to simply start medical optimization (like dabigatran or statins) versus when to trigger an urgent echo, angiogram, or consult, thus preventing the 'troponinemia' reflex that leads to over-testing and prolonged hospitalizations.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MANAGE trial faced significant challenges with patient recruitment and high rates of study drug discontinuation (nearly 46%), leading to a modified intention-to-treat analysis. How do such high rates of treatment discontinuation mathematically impact the statistical power and the specific risks of Type I and Type II errors in evaluating both the primary efficacy and safety endpoints?
Key Response
High discontinuation rates severely bias results toward the null, increasing the risk of a Type II error (failing to detect a true difference) in an intention-to-treat analysis. Methodologically, it drastically reduces the effective sample size and statistical power. Furthermore, it complicates the safety analysis: if half the patients stop taking the anticoagulant, the observed rate of major bleeding will artificially decrease, potentially masking the true hazard of the intervention.
As an editor reviewing this manuscript, how do you reconcile the authors' conclusion that dabigatran did not significantly increase major bleeding with the fact that almost half of the cohort discontinued the study drug prematurely?
Key Response
A seasoned reviewer would immediately flag the 46% discontinuation rate as a massive threat to internal validity, particularly for the safety endpoint. If patients are not actively taking the anticoagulant, the incidence of drug-induced bleeding will inevitably be lower. Editors must demand robust per-protocol or 'on-treatment' sensitivity analyses to ensure that the claim of safety is not merely an artifact of non-adherence, which could lead to harmful real-world applications.
The Canadian Cardiovascular Society (CCS) guidelines advocate for routine MINS screening and suggest dabigatran 110 mg BID for management based largely on MANAGE, whereas ACC/AHA guidelines have historically been more conservative regarding routine perioperative troponin screening. How should international guideline committees reconcile the moderate, single-trial evidence of MANAGE against the massive systemic cost and practice shift required for universal screening?
Key Response
Guideline committees must evaluate the strength of recommendation and level of evidence. MANAGE provides randomized data (albeit with methodological limitations like drug discontinuation) showing benefit in treating MINS. However, recommending dabigatran inherently requires a Class I recommendation for routine post-operative troponin surveillance. Committees must weigh the cost-effectiveness, the risk of false positives, and the potential for bleeding against the mortality benefit seen in addressing MINS, explaining the current divergence between CCS and ACC/AHA recommendations.
Clinical Landscape
Noteworthy Related Trials
POISE Trial
Tested
Extended-release metoprolol
Population
Patients at risk for atherosclerotic disease undergoing noncardiac surgery
Comparator
Placebo
Endpoint
Cardiovascular death, nonfatal myocardial infarction, or nonfatal cardiac arrest at 30 days
POISE-2 Trial
Tested
Aspirin and/or Clonidine
Population
Patients undergoing noncardiac surgery
Comparator
Placebo
Endpoint
Death or nonfatal myocardial infarction at 30 days
COMPASS Trial
Tested
Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg daily
Population
Patients with stable cardiovascular or peripheral artery disease
Comparator
Aspirin 100 mg daily alone
Endpoint
Cardiovascular death, stroke, or myocardial infarction
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis